Literature DB >> 9484783

Down-regulation of nucleophosmin/B23 during retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells.

C Y Hsu1, B Y Yung.   

Abstract

Human promyelocytic leukemia HL-60 cells were induced to undergo granulocytic differentiation by treatment with retinoic acid (RA, 10 microM, 1-5 days). The steady-state level of nucleophosmin/B23 mRNA decreased during the RA-induced differentiation. There was also decrease in the level of total cellular nucleophosmin/B23 protein during the RA-induced differentiation. Stabilization and nuclear run-on assays indicate that the decrease in nucleophosmin/B23 mRNA in RA-treated HL-60 cells was transcriptionally regulated. Unlike c-myc mRNA, there was virtually no decline of nucleophosmin/B23 mRNA during the growth arrest by serum-starvation. The decrease in nucleophosmin/B23 mRNA expression in HL-60 cells subsequent to retinoic acid treatment can thus be attributed to cellular differentiation rather than the growth arrest induced by RA. Nucleophosmin/B23 antisense oligomer treatment significantly potentiated RA-induced cellular differentiation. Results of this study suggest that nucleophosmin/B23 is one of the key elements in the down-regulation of nucleolar function for cellular differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484783     DOI: 10.1038/sj.onc.1201615

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

Review 1.  Insights into the regulation of neuronal viability by nucleophosmin/B23.

Authors:  Jason A Pfister; Santosh R D'Mello
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-22

Review 2.  DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.

Authors:  Ruth A Gjerset
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 2.611

3.  Nucleophosmin is required for DNA integrity and p19Arf protein stability.

Authors:  Emanuela Colombo; Paola Bonetti; Eros Lazzerini Denchi; Paola Martinelli; Raffaella Zamponi; Jean-Christophe Marine; Kristian Helin; Brunangelo Falini; Pier Giuseppe Pelicci
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

4.  Analysis of plausible downstream target genes of Hoxc8 in F9 teratocarcinoma cells. Putative downstream target genes of Hoxc8.

Authors:  Yunjeong Kwon; Jeong Heon Ko; Kim Byung-Gyu; Myoung Hee Kim; Byungkyu Kim
Journal:  Mol Biol Rep       Date:  2003-09       Impact factor: 2.316

5.  NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia.

Authors:  Jessica N Nichol; Matthew D Galbraith; Claudia L Kleinman; Joaquín M Espinosa; Wilson H Miller
Journal:  Cell Rep       Date:  2016-03-17       Impact factor: 9.423

6.  Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23).

Authors:  Angel Chao; Chiao-Yun Lin; Chia-Lung Tsai; Swei Hsueh; Ying-Yu Lin; Cheng-Tao Lin; Hung-Hsueh Chou; Tzu-Hao Wang; Chyong-Huey Lai; Hsin-Shih Wang
Journal:  J Mol Med (Berl)       Date:  2012-08-29       Impact factor: 4.599

7.  Nucleophosmin blocks mitochondrial localization of p53 and apoptosis.

Authors:  Sanjit Kumar Dhar; Daret K St Clair
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

8.  Involvement of PKC in TPA-potentiated apoptosis induction during hemin-mediated erythroid differentiation in K562 cells.

Authors:  Chih Chung Chou; Chen Ya Hsu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-29       Impact factor: 3.000

9.  Sex differences in the acute in vivo effects of different human SP-A variants on the mouse alveolar macrophage proteome.

Authors:  David S Phelps; Todd M Umstead; Joanna Floros
Journal:  J Proteomics       Date:  2014-06-18       Impact factor: 4.044

10.  Sex differences in the response of the alveolar macrophage proteome to treatment with exogenous surfactant protein-A.

Authors:  David S Phelps; Todd M Umstead; Joanna Floros
Journal:  Proteome Sci       Date:  2012-07-23       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.